Evidence map›Paper›PMID 39026644›Full record

ArticleRSC medicinal chemistry2024

Geometric deep learning-guided Suzuki reaction conditions assessment for applications in medicinal chemistry.

Kenneth Atz, David F Nippa, Alex T Müller, Vera Jost, Andrea Anelli, Michael Reutlinger, Christian Kramer, Rainer E Martin, Uwe Grether, Gisbert Schneider and 1 more

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Frugal Sampling Strategies for Navigating Complex Reaction Spaces.Organic process research & development · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. CombiningRSC advances · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenneth AtzRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0002-2628-1619
David F NippaRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0002-0346-3786
Alex T MüllerRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0001-8063-9952
Vera JostRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.
Andrea AnelliRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0001-9230-1342
Michael ReutlingerRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0001-9393-108X
Christian KramerRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0001-8663-5266
Rainer E MartinRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0001-7895-497X
Uwe GretherRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0002-3164-9270
Gisbert SchneiderDepartment of Chemistry and Applied Biosciences, ETH Zurich Vladimir-Prelog-Weg 4 8093 Zurich Switzerland gisbert@ethz.ch.ORCID https://orcid.org/0000-0001-6706-1084
Georg WuitschikRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 4070 Basel Switzerland kenneth.atz@roche.com georg.wuitschik@roche.com.ORCID https://orcid.org/0000-0001-6682-1213

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suzuki cross-coupling reactions are considered a valuable tool for constructing carbon-carbon bonds in small molecule drug discovery. However, the synthesis of chemical matter often represents a time-consuming and labour-intensive bottleneck. We demonstrate how machine learning methods trained on high-throughput experimentation (HTE) data can be leveraged to enable fast reaction condition selection for novel coupling partners. We show that the trained models support chemists in determining suitable catalyst-solvent-base combinations for individual transformations including an evaluation of the need for HTE screening. We introduce an algorithm for designing 96-well plates optimized towards reaction yields and discuss the model performance of zero- and few-shot machine learning. The best-performing machine learning model achieved a three-category classification accuracy of 76.3% (±0.2%) and an

Identifiers

PMID39026644
PMCPMC11253849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.